Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- 7 November 2013
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 369 (19), 1807-1818
- https://doi.org/10.1056/nejmoa1215541
Abstract
Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir–lamivudine, may provide a simplified regimen.Keywords
This publication has 27 references indexed in Scilit:
- Dolutegravir in antiretroviral-naive adults with HIV-1AIDS, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAIDS, 2012
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA ComplexesAntimicrobial Agents and Chemotherapy, 2011
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialThe Lancet, 2011
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase InhibitorAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Designing and interpreting HIV noninferiority trials in naive and experienced patientsAIDS, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirThe New England Journal of Medicine, 2008